A Phase 1, Open-Label, Partially Randomized, 3-Part, Parallel Group Trial to Evaluate the Pharmacokinetic Profile of Glepaglutide (ZP1848) After a Single Intravenous Injection and After Multiple Subcutaneous Injections in Healthy Subjects

Trial Profile

A Phase 1, Open-Label, Partially Randomized, 3-Part, Parallel Group Trial to Evaluate the Pharmacokinetic Profile of Glepaglutide (ZP1848) After a Single Intravenous Injection and After Multiple Subcutaneous Injections in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Glepaglutide (Primary) ; Glepaglutide (Primary)
  • Indications Short bowel syndrome
  • Focus Pharmacokinetics
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 21 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Oct 2017 According to a Zealand Pharma media release, to date, 30 subjects have been dosed in this trial. Results from this trial are expected in Q1 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top